Oral semaglutide (Rybelsus) can be tied to a near halving of incident Afib, according to a meta-analysis of 26 randomized ...

Abbott has reported new data from its prospective, non-randomised Volt CE Mark Study, indicating that individuals treated ...

A system hybridizing cardiac contractility modulation and implantable cardioverter defibrillation successfully converted ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

SGLT2 inhibitors, compared with GLP1 agonists, significantly lower risk for atrial fibrillation in patients with type 2 diabetes.

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

For patients newly diagnosed with atrial fibrillation during hospitalization for other causes, most are not dispensed anticoagulants in the year after discharge.

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

Three risk factors—high blood pressure, atrial fibrillation, and smoking—are more likely to cause severe strokes, meaning ...

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated ...

For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...